vs
Side-by-side financial comparison of Douglas Elliman Inc. (DOUG) and HAEMONETICS CORP (HAE). Click either name above to swap in a different company.
HAEMONETICS CORP is the larger business by last-quarter revenue ($339.0M vs $245.4M, roughly 1.4× Douglas Elliman Inc.). Douglas Elliman Inc. runs the higher net margin — 27.9% vs 13.2%, a 14.7% gap on every dollar of revenue. On growth, Douglas Elliman Inc. posted the faster year-over-year revenue change (0.9% vs -2.7%). HAEMONETICS CORP produced more free cash flow last quarter ($87.2M vs $-14.7M). Over the past eight quarters, Douglas Elliman Inc.'s revenue compounded faster (10.7% CAGR vs 0.4%).
Douglas Elliman Inc. is a leading U.S.-based residential real estate brokerage firm. It offers luxury property sales, rentals, property management, and advisory solutions, serving high-net-worth clients across key metro markets including New York, California, Florida, and Texas.
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
DOUG vs HAE — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $245.4M | $339.0M |
| Net Profit | $68.6M | $44.7M |
| Gross Margin | — | 59.7% |
| Operating Margin | 27.3% | 19.9% |
| Net Margin | 27.9% | 13.2% |
| Revenue YoY | 0.9% | -2.7% |
| Net Profit YoY | 1243.4% | 19.3% |
| EPS (diluted) | $0.80 | $0.95 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $245.4M | $339.0M | ||
| Q3 25 | $262.8M | $327.3M | ||
| Q2 25 | $271.4M | $321.4M | ||
| Q1 25 | $253.4M | $330.6M | ||
| Q4 24 | $243.3M | $348.5M | ||
| Q3 24 | $266.3M | $345.5M | ||
| Q2 24 | $285.8M | $336.2M | ||
| Q1 24 | $200.2M | — |
| Q4 25 | $68.6M | $44.7M | ||
| Q3 25 | $-24.7M | $38.7M | ||
| Q2 25 | $-22.7M | $34.0M | ||
| Q1 25 | $-6.0M | $58.0M | ||
| Q4 24 | $-6.0M | $37.5M | ||
| Q3 24 | $-27.2M | $33.8M | ||
| Q2 24 | $-1.7M | $38.4M | ||
| Q1 24 | $-41.5M | — |
| Q4 25 | — | 59.7% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 59.8% | ||
| Q1 25 | — | 58.4% | ||
| Q4 24 | — | 55.5% | ||
| Q3 24 | — | 54.2% | ||
| Q2 24 | — | 52.0% | ||
| Q1 24 | — | — |
| Q4 25 | 27.3% | 19.9% | ||
| Q3 25 | -4.1% | 17.9% | ||
| Q2 25 | -2.0% | 16.8% | ||
| Q1 25 | -2.1% | 21.6% | ||
| Q4 24 | -6.7% | 16.9% | ||
| Q3 24 | -2.8% | 15.0% | ||
| Q2 24 | -1.3% | 11.8% | ||
| Q1 24 | -20.7% | — |
| Q4 25 | 27.9% | 13.2% | ||
| Q3 25 | -9.4% | 11.8% | ||
| Q2 25 | -8.4% | 10.6% | ||
| Q1 25 | -2.4% | 17.5% | ||
| Q4 24 | -2.5% | 10.8% | ||
| Q3 24 | -10.2% | 9.8% | ||
| Q2 24 | -0.6% | 11.4% | ||
| Q1 24 | -20.7% | — |
| Q4 25 | $0.80 | $0.95 | ||
| Q3 25 | $-0.29 | $0.81 | ||
| Q2 25 | $-0.27 | $0.70 | ||
| Q1 25 | $-0.07 | $1.17 | ||
| Q4 24 | $-0.06 | $0.74 | ||
| Q3 24 | $-0.33 | $0.66 | ||
| Q2 24 | $-0.02 | $0.74 | ||
| Q1 24 | $-0.50 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $115.5M | $363.4M |
| Total DebtLower is stronger | — | $1.2B |
| Stockholders' EquityBook value | $183.9M | $911.5M |
| Total Assets | $444.4M | $2.5B |
| Debt / EquityLower = less leverage | — | 1.34× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $115.5M | $363.4M | ||
| Q3 25 | $143.0M | $296.4M | ||
| Q2 25 | $136.3M | $292.9M | ||
| Q1 25 | $136.8M | $306.8M | ||
| Q4 24 | $145.5M | $320.8M | ||
| Q3 24 | $151.4M | $299.3M | ||
| Q2 24 | $92.9M | $344.4M | ||
| Q1 24 | $91.5M | — |
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.2B | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $183.9M | $911.5M | ||
| Q3 25 | $115.1M | $849.2M | ||
| Q2 25 | $137.6M | $882.3M | ||
| Q1 25 | $158.2M | $820.8M | ||
| Q4 24 | $162.2M | $906.9M | ||
| Q3 24 | $173.6M | $878.9M | ||
| Q2 24 | $196.9M | $905.4M | ||
| Q1 24 | $195.1M | — |
| Q4 25 | $444.4M | $2.5B | ||
| Q3 25 | $480.6M | $2.4B | ||
| Q2 25 | $489.0M | $2.5B | ||
| Q1 25 | $493.9M | $2.5B | ||
| Q4 24 | $493.9M | $2.5B | ||
| Q3 24 | $502.7M | $2.5B | ||
| Q2 24 | $463.9M | $2.5B | ||
| Q1 24 | $461.1M | — |
| Q4 25 | — | 1.34× | ||
| Q3 25 | — | 1.44× | ||
| Q2 25 | — | 1.39× | ||
| Q1 25 | — | 1.49× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-14.4M | $93.6M |
| Free Cash FlowOCF − Capex | $-14.7M | $87.2M |
| FCF MarginFCF / Revenue | -6.0% | 25.7% |
| Capex IntensityCapex / Revenue | 0.1% | 1.9% |
| Cash ConversionOCF / Net Profit | -0.21× | 2.09× |
| TTM Free Cash FlowTrailing 4 quarters | $-17.2M | $308.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-14.4M | $93.6M | ||
| Q3 25 | $5.5M | $111.3M | ||
| Q2 25 | $642.0K | $17.4M | ||
| Q1 25 | $-5.6M | $116.6M | ||
| Q4 24 | $-9.0M | $43.8M | ||
| Q3 24 | $9.0M | $48.8M | ||
| Q2 24 | $1.3M | $-27.4M | ||
| Q1 24 | $-27.3M | — |
| Q4 25 | $-14.7M | $87.2M | ||
| Q3 25 | $4.7M | $106.3M | ||
| Q2 25 | $-575.0K | $13.6M | ||
| Q1 25 | $-6.7M | $100.9M | ||
| Q4 24 | $-10.2M | $35.2M | ||
| Q3 24 | $7.7M | $39.4M | ||
| Q2 24 | $432.0K | $-33.1M | ||
| Q1 24 | $-29.4M | — |
| Q4 25 | -6.0% | 25.7% | ||
| Q3 25 | 1.8% | 32.5% | ||
| Q2 25 | -0.2% | 4.2% | ||
| Q1 25 | -2.6% | 30.5% | ||
| Q4 24 | -4.2% | 10.1% | ||
| Q3 24 | 2.9% | 11.4% | ||
| Q2 24 | 0.2% | -9.8% | ||
| Q1 24 | -14.7% | — |
| Q4 25 | 0.1% | 1.9% | ||
| Q3 25 | 0.3% | 1.5% | ||
| Q2 25 | 0.4% | 1.2% | ||
| Q1 25 | 0.4% | 4.7% | ||
| Q4 24 | 0.5% | 2.5% | ||
| Q3 24 | 0.5% | 2.7% | ||
| Q2 24 | 0.3% | 1.7% | ||
| Q1 24 | 1.0% | — |
| Q4 25 | -0.21× | 2.09× | ||
| Q3 25 | — | 2.88× | ||
| Q2 25 | — | 0.51× | ||
| Q1 25 | — | 2.01× | ||
| Q4 24 | — | 1.17× | ||
| Q3 24 | — | 1.44× | ||
| Q2 24 | — | -0.71× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DOUG
| Commissions And Other Brokerage Income | $240.3M | 98% |
| Property Management Income | $2.8M | 1% |
| Property Management | $2.2M | 1% |
HAE
| Hospital | $143.5M | 42% |
| Plasma Productsand Services | $138.9M | 41% |
| Blood Center Productsand Services | $56.6M | 17% |
